Decipher Test Impacts Post-Op Tx Choice for Prostate Cancer

GenomeDx Biosciences announced data from two studies showing that Decipher Prostate Cancer Classifier significantly altered treatment decisions and increased confidence in treatment decision-making for men considering adjuvant therapy following prostate surgery.

The Decipher Prostate Cancer Classifier assesses the activity of multiple genomic markers associated with metastatic disease and provides information on tumor aggressiveness.

The PRO-ACT study studied 15 board-certified, community-based urologists who had ordered the Decipher test were asked to provide treatment recommendations before and after receiving their patients’ Decipher test results. They were then asked to complete a decision conflict scale to assess confidence in treatment recommendations.

After obtaining Decipher results, physicians changed their recommendations for 30.8% of patients (95% CI: 23–39%). Decipher’s genomic information significantly affected which patients were recommended adjuvant treatment (P<0.001), and the physicians’ decisional conflict was significantly less with the use of Decipher results than without (P<0.0001).

RELATED: FDA-Approved Prostate Cancer Treatments

The ASSESS-D study evaluated 51 community urologists that provided adjuvant treatment recommendations as per clinical guidelines for select patient cases considered high risk for metastasis following prostate surgery. Data showed 31% (95% CI: 27–35%) of treatment recommendations were changed after reviewing the Decipher results.

Treatment intensity was correlated with the Decipher-predicted probability of metastasis (P<0.001) and the Decipher test was the dominant risk factor driving decisions in multivariable analysis (OR=8.6, 95% CI: 5.3–14.3%, P<0.0001).

The studies will be published in the upcoming issues of the journals Current Medical Research and Opinion and the British Journal of Urology International.

For more information call (888) 792-1601 or visit